KMT2A and leukemia: In preclinical models of KMT2A-r leukemia these molecules disrupt the menin-KMT2A interaction and inhibit the chromatin occupancy of menin and KMT2A at select KMT2A target genes leading to pronounced suppression of predominantly MEIS1, but also HOXA genes.